Hologic, Inc. (NASDAQ:HOLX) Shares Sold by Sentry Investment Management LLC

Sentry Investment Management LLC reduced its position in shares of Hologic, Inc. (NASDAQ:HOLX) by 9.7% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,284 shares of the medical equipment provider’s stock after selling 138 shares during the period. Sentry Investment Management LLC’s holdings in Hologic were worth $92,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Commonwealth of Pennsylvania Public School Empls Retrmt SYS boosted its position in shares of Hologic by 5.1% during the 1st quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 33,448 shares of the medical equipment provider’s stock worth $2,569,000 after acquiring an additional 1,631 shares in the last quarter. LSV Asset Management boosted its holdings in Hologic by 307.5% in the first quarter. LSV Asset Management now owns 37,900 shares of the medical equipment provider’s stock valued at $2,911,000 after purchasing an additional 28,600 shares in the last quarter. Raymond James Trust N.A. increased its stake in Hologic by 7.4% in the first quarter. Raymond James Trust N.A. now owns 6,875 shares of the medical equipment provider’s stock valued at $528,000 after purchasing an additional 476 shares during the last quarter. Dimensional Fund Advisors LP raised its holdings in Hologic by 4.8% during the first quarter. Dimensional Fund Advisors LP now owns 2,305,399 shares of the medical equipment provider’s stock worth $177,098,000 after purchasing an additional 106,315 shares in the last quarter. Finally, Aviva PLC lifted its position in shares of Hologic by 0.7% during the 1st quarter. Aviva PLC now owns 75,543 shares of the medical equipment provider’s stock worth $5,803,000 after buying an additional 513 shares during the last quarter. Institutional investors and hedge funds own 94.73% of the company’s stock.

Insiders Place Their Bets

In other news, CFO Karleen Marie Oberton sold 14,940 shares of the firm’s stock in a transaction on Monday, January 29th. The shares were sold at an average price of $75.00, for a total value of $1,120,500.00. Following the completion of the sale, the chief financial officer now owns 103,916 shares in the company, valued at approximately $7,793,700. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. In related news, CFO Karleen Marie Oberton sold 14,940 shares of the stock in a transaction dated Monday, January 29th. The shares were sold at an average price of $75.00, for a total transaction of $1,120,500.00. Following the completion of the transaction, the chief financial officer now directly owns 103,916 shares of the company’s stock, valued at $7,793,700. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Charles J. Dockendorff sold 1,465 shares of the firm’s stock in a transaction dated Friday, March 8th. The shares were sold at an average price of $76.21, for a total transaction of $111,647.65. Following the completion of the sale, the director now owns 1,572 shares of the company’s stock, valued at approximately $119,802.12. The disclosure for this sale can be found here. In the last quarter, insiders sold 32,846 shares of company stock worth $2,473,443. 1.75% of the stock is owned by insiders.

Analyst Ratings Changes

A number of research firms recently commented on HOLX. StockNews.com downgraded shares of Hologic from a “buy” rating to a “hold” rating in a research report on Friday, March 8th. Needham & Company LLC reiterated a “buy” rating and set a $90.00 target price on shares of Hologic in a research report on Wednesday, April 10th. Raymond James boosted their target price on Hologic from $85.00 to $88.00 and gave the company an “outperform” rating in a report on Friday, February 2nd. Evercore ISI raised their price target on Hologic from $76.00 to $78.00 and gave the stock an “in-line” rating in a research note on Thursday, April 4th. Finally, Citigroup upgraded Hologic from a “neutral” rating to a “buy” rating and boosted their price objective for the company from $80.00 to $95.00 in a research note on Wednesday, April 3rd. Six analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $87.00.

Hologic Stock Up 0.2 %

HOLX opened at $75.10 on Friday. Hologic, Inc. has a 52 week low of $64.02 and a 52 week high of $87.88. The business has a 50 day moving average price of $75.71 and a two-hundred day moving average price of $72.50. The company has a quick ratio of 3.18, a current ratio of 3.89 and a debt-to-equity ratio of 0.55. The company has a market cap of $17.63 billion, a PE ratio of 35.59, a P/E/G ratio of 2.54 and a beta of 1.00.

Hologic (NASDAQ:HOLX) last released its earnings results on Thursday, February 1st. The medical equipment provider reported $0.98 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.95 by $0.03. Hologic had a return on equity of 18.91% and a net margin of 12.98%. The business had revenue of $1.01 billion for the quarter, compared to analyst estimates of $989.32 million. During the same quarter in the previous year, the company posted $1.07 earnings per share. The company’s revenue for the quarter was down 5.7% compared to the same quarter last year. As a group, research analysts anticipate that Hologic, Inc. will post 4.02 EPS for the current year.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.